Venetoclax with azacitidine versus standard chemotherapy after remission in high-risk acute myeloid leukemia
Compares two treatments before transplant in adults with high-risk acute myeloid leukemia in remission.
Plain-language title generated from the registry record
Registry title: Venetoclax Combined With Azacitidine for Consolidation Therapy in AML
Key facts
- Where
- Suzhou, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed high-risk acute myeloid leukemia who are in remission after venetoclax and azacitidine and plan to have a stem cell transplant.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- High-risk acute myeloid leukemia (AML), including AML with myelodysplasia-related changes and therapy-related AML, in complete remission (CR or CRi) after 2 or fewer cycles of venetoclax and azacitidine induction.
- Earlier treatment
- Must have had 2 or fewer cycles of venetoclax and azacitidine induction treatment, with a donor available and an allogeneic stem cell transplant planned.
Main reasons for not taking part
- Active heart disease, such as uncontrolled heart rhythm problems, heart failure, or a heart attack within 3 months
- Leukemia in the brain or spinal fluid, or outside the bone marrow
- Known HIV infection or uncontrolled severe viral hepatitis
- Pregnant or breastfeeding women
- Other serious illness, such as severe infection or kidney failure
Read by machine on 9 November 2026.
Where in China
- the First Affiliated Hosptital of Soochow UniversitySuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital of Soochow University
- Trial code
- NCT07425782
- Record updated
- 6 August 2026
- Original description
The goal of this clinical trial is to compare the efficacy and safety of a venetoclax-based consolidation therapy versus conventional consolidation chemotherapy in newly diagnosed adult patients with high-risk acute myeloid leukemia (AML) who have achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi) after induction therapy with venetoclax and azacitidine and are planned for transplantation.Read full original descriptionShow less
A Prospective, Randomized, Open-Label Study of Venetoclax Combined With Azacitidine for Consolidation Therapy in Adult Acute Myeloid Leukemia
The goal of this clinical trial is to compare the efficacy and safety of a venetoclax-based consolidation therapy versus conventional consolidation chemotherapy in newly diagnosed adult patients with high-risk acute myeloid leukemia (AML) who have achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi) after induction therapy with venetoclax and azacitidine and are planned for transplantation.
The main questions it aims to answer are:
Does consolidation therapy with a venetoclax-containing regimen lead to superior clinical outcomes compared to conventional chemotherapy in this specific patient population? What is the comparative safety profile of the venetoclax-containing consolidation regimen versus conventional chemotherapy in these patients? Participants will be randomly assigned to receive either the venetoclax-based consolidation therapy or the conventional consolidation chemotherapy before undergoing transplantation.
Inclusion: Diagnosis of AML confirmed by bone marrow morphology, flow cytometry, and molecular genetics, meeting WHO 2022 classification criteria; Age ≥ 18 years; Classified as high-risk according to the European LeukemiaNet (ELN) prognostic risk stratification for AML, including AML with myelodysplasia-related changes (AML-MRC) and therapy-related acute myeloid leukemia (t-AML); Achieved CR or CRi after ≤ 2 cycles of VA induction chemotherapy; Availability of a suitable donor, with plans to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT); Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2; Creatinine clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal (ULN), total bilirubin ≤ 2 times ULN; left ventricular ejection fraction (LVEF) ≥ 50% as shown by echocardiography (ECHO); expected survival > 8 weeks; Voluntarily signed the informed consent form and can understand and comply with study requirements.
Exclusion: Presence of clinically active cardiovascular disease, such as uncontrolled ventricular arrhythmia, uncontrolled hypertension, congestive heart failure, cardiac disease classified as Class 3 or 4 according to the New York Heart Association (NYHA) Functional Classification, or a history of myocardial infarction within 3 months prior to screening; Other serious diseases that may limit the patient's participation in this trial (e.g., severe infection, renal failure); Known human immunodeficiency virus (HIV) infection or uncontrolled severe viral hepatitis; Any other conditions deemed by the investigator as unsuitable for participation in this study; Active central nervous system leukemia (CNSL) or extramedullary infiltration of leukemia; Pregnant or breastfeeding women; Inability to understand, comply with the study protocol, or sign the informed consent form.